Study: LTX-315 Shows 86% Reduction in BCC Tumor Size

Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC).

The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the results showed an 86% overall reduction in tumor size among patients, with complete clearance of tumors achieved in 51% of participants. The trial population included 93 patients with BCC. Additionally, the safety profile was favorable and no severe adverse events were recorded.

Notably, patients with residual carcinomas experienced a 71% average reduction in tumor size. The authors said that the findings suggest that LTX-315 could be utilized as a first-line therapy for BCC, potentially in combination with surgery, and that the results mark a significant step forward in bringing the candidate drug closer to commercialization.

“Together with our partner Verrica, we’re immensely proud of these results, showing that our lead drug candidate LTX-315 has a powerful anticancer effect in basal cell carcinoma," Dr. Øystein Rekdal, CEO of Lytix Biopharma, said in a press release. "It has the potential to be used either alone or in combination with surgery in early lines of treatment in this vast cancer population."

Source: Lytix Biopharma press release. August 14, 2024.